MX2019012884A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2019012884A
MX2019012884A MX2019012884A MX2019012884A MX2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A
Authority
MX
Mexico
Prior art keywords
combination
proliferative disease
treatment
subject
combination therapy
Prior art date
Application number
MX2019012884A
Other languages
English (en)
Inventor
Cooke Vesselina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62218018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019012884A publication Critical patent/MX2019012884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende (a) un inhibidor de Raf conforme lo definido en la presente, o una sal farmacéuticamente aceptable del mismo y (b) un inhibidor de MEK, particularmente trametinib, particularmente para usarse en el tratamiento de una enfermedad proliferativa. La presente invención además se refiere a usos de esta combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; a métodos de tratamiento de una enfermedad proliferativa en un sujeto que lo necesite que comprenden administrar a dicho sujeto una cantidad conjuntamente terapéuticamente efectiva de dicha combinación; al uso de tal combinación para el tratamiento de una enfermedad proliferativa; a composiciones farmacéuticas que comprenden tal combinación y a envases comerciales para las mismas.
MX2019012884A 2017-05-02 2018-04-30 Terapia de combinacion. MX2019012884A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500108P 2017-05-02 2017-05-02
US201862656423P 2018-04-12 2018-04-12
PCT/IB2018/052989 WO2018203219A1 (en) 2017-05-02 2018-04-30 Combination therapy

Publications (1)

Publication Number Publication Date
MX2019012884A true MX2019012884A (es) 2020-01-14

Family

ID=62218018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012884A MX2019012884A (es) 2017-05-02 2018-04-30 Terapia de combinacion.

Country Status (18)

Country Link
US (2) US11266653B2 (es)
EP (2) EP3618875B1 (es)
JP (2) JP7309614B2 (es)
KR (2) KR102641827B1 (es)
CN (1) CN110494166B (es)
AU (1) AU2018262891B2 (es)
BR (1) BR112019022511A2 (es)
CA (1) CA3057969A1 (es)
CL (1) CL2019003091A1 (es)
DK (1) DK3618875T3 (es)
ES (1) ES2952265T3 (es)
FI (1) FI3618875T3 (es)
IL (1) IL270224B1 (es)
MX (1) MX2019012884A (es)
PL (1) PL3618875T3 (es)
PT (1) PT3618875T (es)
TW (1) TWI798218B (es)
WO (1) WO2018203219A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3665302A4 (en) * 2017-08-11 2021-04-28 Curematch, Inc. COMBINED MEDICINAL PRODUCTS AGAINST MULTIPLE MUTATIONS IN CANCER
JP2022514056A (ja) * 2018-12-20 2022-02-09 ノバルティス アーゲー 癌の治療に使用するためのＲａｆ阻害剤及びＣＤＫ４／６阻害剤による組み合わせ療法
TW202140029A (zh) * 2020-02-18 2021-11-01 瑞士商諾華公司 用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合
AU2021226119B2 (en) * 2020-02-27 2024-04-18 National University Corporation Hokkaido University Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
EP4149472A1 (en) * 2020-05-12 2023-03-22 Novartis AG Therapeutic combinations comprising a craf inhibitor
EP4203963A1 (en) * 2020-08-31 2023-07-05 Novartis AG Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
TW202342766A (zh) 2022-03-02 2023-11-01 瑞士商諾華公司 用於癌症治療之精準療法
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
BRPI0511967B8 (pt) 2004-06-11 2021-05-25 Japan Tobacco Inc derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EP3981408A1 (en) 2012-09-04 2022-04-13 Novartis AG Dabrafenib and trametinib in a method of adjuvant cancer treatment
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10973829B2 (en) 2016-09-19 2021-04-13 Novartis Ag Therapeutic uses of a C-RAF inhibitor

Also Published As

Publication number Publication date
RU2019134757A3 (es) 2021-08-17
AU2018262891A1 (en) 2019-10-17
CN110494166B (zh) 2022-11-08
CA3057969A1 (en) 2018-11-08
KR20190141164A (ko) 2019-12-23
IL270224B1 (en) 2024-04-01
EP3618875B1 (en) 2023-04-05
AU2018262891B2 (en) 2021-04-01
CL2019003091A1 (es) 2020-02-07
DK3618875T3 (da) 2023-07-10
FI3618875T3 (fi) 2023-07-04
JP2023145467A (ja) 2023-10-11
BR112019022511A2 (pt) 2020-05-12
RU2019134757A (ru) 2021-06-02
IL270224A (es) 2019-12-31
TWI798218B (zh) 2023-04-11
JP7309614B2 (ja) 2023-07-18
PT3618875T (pt) 2023-08-07
US20200246346A1 (en) 2020-08-06
KR20240032157A (ko) 2024-03-08
TW201842914A (zh) 2018-12-16
CN110494166A (zh) 2019-11-22
EP3618875A1 (en) 2020-03-11
US11266653B2 (en) 2022-03-08
EP4272740A1 (en) 2023-11-08
WO2018203219A1 (en) 2018-11-08
KR102641827B1 (ko) 2024-03-04
PL3618875T3 (pl) 2023-10-23
US20220143036A1 (en) 2022-05-12
JP2020518568A (ja) 2020-06-25
ES2952265T3 (es) 2023-10-30

Similar Documents

Publication Publication Date Title
MX2019012884A (es) Terapia de combinacion.
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2021002321A (es) Nuevos metodos.
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA033298B1 (ru) Комбинированная лекарственная форма тезофензина и метопролола
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2021002322A (es) Nuevos metodos.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.
ZA202200330B (en) Pharmaceutical composition of imatinib
RU2020101999A (ru) Ликофлигозин для лечения неалкогольного стеатогепатита